Project Details
| Short title | XL184-315 |
|---|---|
| Acronym | CONTACT-02 |
| Status | Finished |
| Effective start/end date | 3/09/21 → 29/04/26 |
A phase 3 randomized, open label, controlled study of cabozantinib (XL184) in combination with Atezolizumab vs second novel hormonal therapy in subjects with high-risk, metastatic castration-resistant prostate cancer
- Gurney, Howard (Primary Chief Investigator)
- Zhang, Alison (Associate Investigator)
- Chapman, Nicola (Clinical Trial Unit Staff)
Project: Research